CardioTeca CardioTeca CardioTeca CardioTeca
ESPACIO Lípidos

Biblioteca de referencias

Detalles
G
ESPACIO de lípidos › Bloque G › G4

Guías y evidencia

Lo que recomiendan las guías y lo que demuestran los estudios, separando siempre lo aprobado de lo que se investiga.

G4

Todas las fuentes citadas en el ESPACIO, en formato Vancouver, con DOI y PMID verificados, filtrables por tema y descargables para un gestor bibliográfico.

La evidencia en el tiempo: los artículos y guías citados en este ESPACIO, por año (2 anteriores a 1990, fuera del eje)

51015202530354011111322412313322665513159201820233819901995200020052010201520202025
250referencias: 213 artículos y guías, comprobados en PubMed y Crossref, y 37 fichas técnicas81de 2024, 2025 y 202627guías, consensos y declaraciones científicas

La lista se hace sola con lo que citan las páginas de este ESPACIO y se descarga en RIS.

Descargar en RIS (250 referencias)

Artículos y guías en PubMed (211)

  1. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-74. doi:10.1056/NEJMoa1001282 · PMID 20228404C5G2I1
  2. Alonso R, Arroyo-Olivares R, Muñiz-Grijalvo O, Díaz-Díaz JL, Muñoz-Torrero JS, Romero MJ, et al. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study. Eur J Prev Cardiol. 2023;30(4):320-328. doi:10.1093/eurjpc/zwac277 · PMID 36416136G3
  3. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-59. doi:10.1056/NEJMoa061894 · PMID 16899775C5C6G2I1
  4. Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Béjot Y, et al. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med. 2020;382(1):9. doi:10.1056/NEJMoa1910355 · PMID 31738483C6G2
  5. Ambardekar AV, Bhatt A, Hoekstra M, Kelly MA, Musunuru K, Natarajan P. Gene Editing Therapy in Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. J Am Coll Cardiol. 2026;88(10):1157-1173. doi:10.1016/j.jacc.2026.02.5092 · PMID 41885675G5
  6. Aragona CO, Bianco A, Caruso R, Cerulli M, Cosentino N, Cittadini A, et al. Lipid-lowering therapy in patients with coronary heart disease: an Italian real-life survey. Results from the Survey on Risk FactOrs and CardiovascuLar secondary prEvention and drug strategieS (SOFOCLES) in Italy. Monaldi Arch Chest Dis. 2025;95(3). doi:10.4081/monaldi.2024.2972 · PMID 39259232G3
  7. Arca M, Celant S, Olimpieri PP, Colatrella A, Tomassini L, D'Erasmo L, et al. Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries. J Am Heart Assoc. 2023;12(21):e026550. doi:10.1161/JAHA.122.026550 · PMID 37850449G3
  8. Arrobas Velilla T, Martin Perez S, Fernández Prendes C, Castro Castro MJ, Camos Anguila S, Leon Justel A, et al. Analysis of lipoprotein (a) determination in a selection of Spanish Clinical Laboratories. Batary study. Clin Investig Arterioscler. 2025;37(6):500798. doi:10.1016/j.arteri.2025.500798 · PMID 40180852G3H2
  9. ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, et al. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med. 2018;379(16):1540-1550. doi:10.1056/NEJMoa1804989 · PMID 30146932C5G2I1
  10. Baena-Díez JM, Félix FJ, Grau M, Cabrera de León A, Sanz H, Leal M, et al. Tratamiento y control de los factores de riesgo según el riesgo coronario en la población española del estudio DARIOS. Rev Esp Cardiol. 2011;64(9):766-73. doi:10.1016/j.recesp.2011.04.019 · PMID 21764497H2
  11. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-92. doi:10.1016/S0140-6736(11)60739-3 · PMID 21663949C5C6G2I1
  12. Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, et al. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. N Engl J Med. 2024;391(10):899-912. doi:10.1056/NEJMoa2404143 · PMID 38804517G5
  13. Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA, et al. Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. JAMA. 2026;335(2):129-139. doi:10.1001/jama.2025.20620 · PMID 41206969G5
  14. Barrios V, Escobar C, Llisterri JL, Rodríguez Roca G, Badimón JJ, Vergara J, et al. Características clínicas basales y manejo de los pacientes incluidos en el estudio IBERICAN. Semergen. 2015;41(1):3-12. doi:10.1016/j.semerg.2014.09.010 · PMID 25459384G3
  15. Bergmark BA, Marston NA, Prohaska TA, Alexander VJ, Zimerman A, Moura FA, et al. Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. N Engl J Med. 2025;393(13):1279-1291. doi:10.1056/NEJMoa2507227 · PMID 40888739G5I1
  16. Berwanger O, Santucci EV, de Barros E Silva PGM, Jesuíno IA, Damiani LP, Barbosa LM, et al. Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. JAMA. 2018;319(13):1331-1340. doi:10.1001/jama.2018.2444 · PMID 29525821H4
  17. Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000;102(1):21-7. doi:10.1161/01.cir.102.1.21 · PMID 10880410C5I1
  18. Bhatt AS, Liu VX, Sun B, Apostol-Largeteau M, Marafino BJ, Amiri M, et al. Digital Outreach to Improve Statin Refills in Patients With Low Statin Adherence: The ADHERE-ASCVD Randomized Clinical Trial. JAMA. 2026;doi: 10.1001/jama.2026.16372. doi:10.1001/jama.2026.16372 · PMID 42667613G2
  19. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi:10.1056/NEJMoa1812792 · PMID 30415628C5G2I1
  20. Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, Bittner VA, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026;87(19):2624-2757. doi:10.1016/j.jacc.2025.11.016 · PMID 41824590G5I2
  21. Bohula EA, Marston NA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, et al. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. N Engl J Med. 2026;394(2):117-127. doi:10.1056/NEJMoa2514428 · PMID 41211925C5C7G2G5I1
  22. Brandts J, Barkas F, De Bacquer D, Jennings C, De Backer GG, Kotseva K, et al. International patterns in lipid management and implications for patients with coronary heart disease: results from the INTERASPIRE study. Eur J Prev Cardiol. 2025;pii: zwaf388. doi: 10.1093/eurjpc/zwaf388. doi:10.1093/eurjpc/zwaf388 · PMID 40796307C8
  23. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826. doi:10.1093/eurheartj/ehad191 · PMID 37622654G1H4
  24. Bytyçi I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213-3223. doi:10.1093/eurheartj/ehac015 · PMID 35169843C4C8
  25. Bäck M, Wilhelm M, Marcin T, Machado FVC, Sandberg A, Buccheri S, et al. 2026 ESC Guidelines on cardiac rehabilitation. Eur Heart J. 2026;47(39):5631-5729. doi:10.1093/eurheartj/ehag099 · PMID 42661418D1G1
  26. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-504. doi:10.1056/NEJMoa040583 · PMID 15007110C5G2
  27. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387-97. doi:10.1056/NEJMoa1410489 · PMID 26039521C5G2H4I1
  28. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022;387(11):967-977. doi:10.1056/NEJMoa2208275 · PMID 36018037G2
  29. Catapano AL, Mikhailova E, Navar AM, Banka P, Corral P, Saxena M, et al. Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial. J Am Coll Cardiol. 2026;88(3):340-352. doi:10.1016/j.jacc.2026.03.036 · PMID 42017875G5
  30. Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol. 2022;16(4):361-375. doi:10.1016/j.jacl.2022.05.068 · PMID 35718660C4G1
  31. Cho L, Nicholls SJ, Nordestgaard BG, Landmesser U, Tsimikas S, Blaha MJ, et al. Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a). Am Heart J. 2025;287:1-9. doi:10.1016/j.ahj.2025.03.019 · PMID 40185318G5H3
  32. Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397-405. doi:10.1016/S0140-6736(14)61368-4 · PMID 25579834C6
  33. Cholesterol Treatment Trialists' (CTT) Collaboration. Electronic address: Esta dirección de correo electrónico está siendo protegida contra los robots de spam. Necesita tener JavaScript habilitado para poder verlo., Cholesterol Treatment Trialists' (CTT) Collaboration. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials. Lancet. 2026;407(10529):689-703. doi:10.1016/S0140-6736(25)01578-8 · PMID 41655587C4C7C8G2I2
  34. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407-415. doi:10.1016/S0140-6736(18)31942-1 · PMID 30712900C6G2
  35. Cholesterol Treatment Trialists' Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022;400(10355):832-845. doi:10.1016/S0140-6736(22)01545-8 · PMID 36049498C4C7C8G2I2
  36. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81. doi:10.1016/S0140-6736(10)61350-5 · PMID 21067804C5C7G2
  37. Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940-8. doi:10.1093/eurheartj/eht295 · PMID 23907142C8
  38. Cinza Sanjurjo S, Prieto Díaz MÁ, Llisterri Caro JL, Pallarés Carratalá V, Barquilla García A, Rodríguez Padial L, et al. Características basales y manejo clínico de los primeros 3.000 pacientes incluidos en el estudio IBERICAN (Identificación de la población española de riesgo cardiovascular y renal). Semergen. 2017;43(7):493-500. doi:10.1016/j.semerg.2016.07.006 · PMID 27567214G3H2
  39. Cinza-Sanjurjo S, Micó-Pérez RM, Velilla-Zancada S, Prieto-Díaz MA, Rodríguez-Roca GC, Barquilla García A, et al. Factores asociados al riesgo cardiovascular y enfermedad cardiovascular y renal en el estudio IBERICAN (Identificación de la poBlación Española de RIesgo CArdiovascular y reNal): resultados definitivos. Semergen. 2020;46(6):368-378. doi:10.1016/j.semerg.2020.06.027 · PMID 32873502G3
  40. Civeira F, Jarauta E, Marco-Benedí V, Bea AM, Mateo-Gallego R, Lamiquiz-Moneo I, et al. Classification, prevalence and cardiovascular risk of different types of hypercholesterolemia. Rev Esp Cardiol (Engl Ed). 2026;79(2):131-141. doi:10.1016/j.rec.2025.07.004 · PMID 40783169G3H2
  41. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-96. doi:10.1016/S0140-6736(04)16895-5 · PMID 15325833C5C6G2
  42. Cordero A, Fernández Del Olmo MR, Cortez Quiroga GA, Romero-Menor C, Fácila L, Seijas-Amigo J, et al. Sex Differences in Low-Density Lipoprotein Cholesterol Reduction With PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry. J Cardiovasc Pharmacol. 2022;79(4):523-529. doi:10.1097/FJC.0000000000001205 · PMID 34983910G3
  43. Cordero A, Fernández Olmo MR, Cortez Quiroga GA, Romero-Menor C, Fácila L, Seijas-Amigo J, et al. Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry. Eur J Clin Invest. 2022;52(12):e13863. doi:10.1111/eci.13863 · PMID 36039486G3
  44. Cosín-Sales J, Campuzano Ruiz R, Díaz Díaz JL, Escobar Cervantes C, Fernández Olmo MR, Gómez-Doblas JJ, et al. Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain. Atherosclerosis. 2023;375:38-44. doi:10.1016/j.atherosclerosis.2023.04.013 · PMID 37245425C8
  45. Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. Eur Heart J. 2023;44(25):2277-2291. doi:10.1093/eurheartj/ehad197 · PMID 37130090G1H3
  46. Damman K, Ter Maaten JM, Mayne KJ, Bolignano D, Brown EM, da Costa BR, et al. 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA). Eur Heart J. 2026;pii: ehag098. doi: 10.1093/eurheartj/ehag098. doi:10.1093/eurheartj/ehag098 · PMID 42661426C3C6G1
  47. Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med. 2022;387(21):1923-1934. doi:10.1056/NEJMoa2210645 · PMID 36342113G2G5
  48. De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner Ž, Rydén L, et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135-146. doi:10.1016/j.atherosclerosis.2019.03.014 · PMID 31054483G3
  49. De Backer J, Haugaa KH, Hasselberg NE, de Hosson M, Brida M, Castelletti S, et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. Eur Heart J. 2025;46(43):4462-4568. doi:10.1093/eurheartj/ehaf193 · PMID 40878294C6G1I2
  50. de Isla LP, Vallejo-Vaz AJ, Watts GF, Muñiz-Grijalvo O, Alonso R, Diaz-Diaz JL, et al. Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicentre, prospective cohort study. Lancet Diabetes Endocrinol. 2024;12(9):643-652. doi:10.1016/S2213-8587(24)00192-X · PMID 39098315G3
  51. Delgado-Lista J, Mostaza JM, Arrobas-Velilla T, Blanco-Vaca F, Masana L, Pedro-Botet J, et al. Consensus on lipoprotein(a) of the Spanish Society of Arteriosclerosis. Literature review and recommendations for clinical practice. Clin Investig Arterioscler. 2024;36(4):243-266. doi:10.1016/j.arteri.2024.03.002 · PMID 38599943C7G1H3
  52. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-22. doi:10.1001/jama.279.20.1615 · PMID 9613910C5I1
  53. EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet. 2021;398(10312):1713-1725. doi:10.1016/S0140-6736(21)01122-3 · PMID 34506743G3
  54. Ellis KL, Pérez de Isla L, Alonso R, Fuentes F, Watts GF, Mata P. Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia. J Am Coll Cardiol. 2019;73(9):1029-1039. doi:10.1016/j.jacc.2018.12.037 · PMID 30846097G3H3
  55. Escobar-Cervantes C, Villa G, Campos-Tapias I, Sorio-Vilela F, Lozano J, Kahangire DA, et al. Achieving Lower LDL-C Levels After a Recent Myocardial Infarction Might Be Associated with Lower Healthcare Resource Use and Costs in Spain. Adv Ther. 2022;39(8):3578-3588. doi:10.1007/s12325-022-02187-1 · PMID 35689725H2
  56. European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration. Familial hypercholesterolaemia in children and adolescents from 48 countries: a cross-sectional study. Lancet. 2024;403(10421):55-66. doi:10.1016/S0140-6736(23)01842-1 · PMID 38101429G3
  57. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395-407. doi:10.1056/NEJMoa0810177 · PMID 19332456C5C6G2I1
  58. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631-9. doi:10.1016/j.jacc.2012.09.017 · PMID 23083789H1
  59. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144 · PMID 28444290H1
  60. Ferrières J, Ray KK, Catapano AL, Allouche R, Becker C, Bardet A, et al. Lipid management in high cardiovascular risk patients in France: a comparison with rest of Europe patients from 1-year follow-up of SANTORINI. Front Cardiovasc Med. 2026;13:1748457. doi:10.3389/fcvm.2026.1748457 · PMID 41908045G3
  61. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317(20):1237-45. doi:10.1056/NEJM198711123172001 · PMID 3313041C5I1
  62. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502. PMID 4337382H5
  63. Galve E, Cordero A, Cequier A, Ruiz E, González-Juanatey JR. Degree of Lipid Control in Patients With Coronary Heart Disease and Measures Adopted by Physicians. REPAR Study. Rev Esp Cardiol (Engl Ed). 2016;69(10):931-938. doi:10.1016/j.rec.2016.02.012 · PMID 27178117G3
  64. Garcia-Gil M, Alves-Cabratosa L, Cunillera O, Blanch J, Martí-Lluch R, Ponjoan A, et al. Effectiveness of the low-density lipoprotein cholesterol goals in secondary cardiovascular prevention. Eur J Clin Invest. 2024;54(9):e14258. doi:10.1111/eci.14258 · PMID 38828496G3
  65. García-Villarino M, Lambert C, González-Vidal T, García AV, Villa-Fernández E, Lozano-Aida C, et al. Lipid Profile Management in Secondary Prevention in Spain: Data from the BDCAP Registry in Spain (LIPIDSPAIN). J Clin Med. 2025;14(17). doi:10.3390/jcm14176037 · PMID 40943795G3H2
  66. García-Villarino M, Lozano-Aida C, Suárez-Gutiérrez L, Lambert C, González-Vidal T, García AV, et al. Use of Lipid-Lowering Treatment in Primary Prevention in Spain (Lipidspain). J Clin Med. 2025;14(17). doi:10.3390/jcm14176059 · PMID 40943816G3H2
  67. Gaudet D, Pall D, Watts GF, Nicholls SJ, Rosenson RS, Modesto K, et al. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial. JAMA Cardiol. 2024;9(7):620-630. doi:10.1001/jamacardio.2024.0959 · PMID 38583092G5
  68. Gavina C, Araújo F, Teixeira C, Ruivo JA, Corte-Real AL, Luz-Duarte L, et al. Sex differences in LDL-C control in a primary care population: The PORTRAIT-DYS study. Atherosclerosis. 2023;384:117148. doi:10.1016/j.atherosclerosis.2023.05.017 · PMID 37302923G3
  69. Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, et al. Cognitive Function in a Randomized Trial of Evolocumab. N Engl J Med. 2017;377(7):633-643. doi:10.1056/NEJMoa1701131 · PMID 28813214G2
  70. Giugliano RP, Bohula EA, Bellavia A, De Ferrari GM, Leiter LA, Nicolau JC, et al. Effects of Evolocumab on Mortality Outcomes in Patients Without Previous Myocardial Infarction or Stroke: A Prespecified Analysis of the VESALIUS-CV Randomized Clinical Trial. Circulation. 2026;doi: 10.1161/CIRCULATIONAHA.126.082436. doi:10.1161/CIRCULATIONAHA.126.082436 · PMID 42670293C7G2I1
  71. Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019;322(18):1780-1788. doi:10.1001/jama.2019.16585 · PMID 31714986G2
  72. Gragnano F, Artana C, Carrara G, Sacco A, Montalto C, Mennuni M, et al. Diagnostic and therapeutic inertia for LDL cholesterol management of consecutively verified patients with acute myocardial infarction. Eur J Intern Med. 2026;152:106990. doi:10.1016/j.ejim.2026.106990 · PMID 42321132C8
  73. Grau M, Elosua R, Cabrera de León A, Guembe MJ, Baena-Díez JM, Vega Alonso T, et al. Factores de riesgo cardiovascular en España en la primera década del siglo xxi: análisis agrupado con datos individuales de 11 estudios de base poblacional, estudio DARIOS. Rev Esp Cardiol. 2011;64(4):295-304. doi:10.1016/j.recesp.2010.11.005 · PMID 21397375H2
  74. Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, et al. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection. N Engl J Med. 2023;389(8):687-699. doi:10.1056/NEJMoa2304146 · PMID 37486775C5C6G2I1
  75. Guallar-Castillón P, Gil-Montero M, León-Muñoz LM, Graciani A, Bayán-Bravo A, Taboada JM, et al. Magnitude and management of hypercholesterolemia in the adult population of Spain, 2008-2010: The ENRICA Study. Rev Esp Cardiol (Engl Ed). 2012;65(6):551-8. doi:10.1016/j.recesp.2012.02.005 · PMID 22483404G3H2
  76. Gámez JM, Ripoll T, Barrios V, Anguita M, Pedreira M, Madariaga I, et al. The clinical profile of women with stable ischaemic heart disease in Spain. More effort is needed in secondary prevention. SIRENA study. Rev Clin Esp (Barc). 2016;216(1):1-7. doi:10.1016/j.rce.2015.09.012 · PMID 26548859G3
  77. Gómez-Barrado JJ, Gómez-Turégano P, Beltrán Moreno M, Fernández-Chamorro AI, Roque Rodríguez B, Kounka Z. Lipoprotein (a) is a predictor of non-achievement of LDL-C goals in patients with chronic heart disease. Clin Investig Arterioscler. 2024;36(5):278-285. doi:10.1016/j.arteri.2024.01.002 · PMID 38402025H2
  78. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43(39):3826-3924. doi:10.1093/eurheartj/ehac270 · PMID 36017553G1I2
  79. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22. doi:10.1016/S0140-6736(02)09327-3 · PMID 12114036C5G2I1
  80. Herrett E, Williamson E, Brack K, Beaumont D, Perkins A, Thayne A, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021;372:n135. doi:10.1136/bmj.n135 · PMID 33627334C4C8
  81. Hilgendorf I, Westermann D, Nowak B, Uebel P, Dürsch M, Mahabadi AA, et al. Inclisiran vs bempedoic acid for low-density lipoprotein cholesterol lowering in high-risk patients: the VICTORION-Challenge trial. Eur Heart J. 2026;pii: ehag738. doi: 10.1093/eurheartj/ehag738. doi:10.1093/eurheartj/ehag738 · PMID 42670194C5G2
  82. Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361(9374):2024-31. doi:10.1016/S0140-6736(03)13638-0 · PMID 12814712C6I1
  83. Hong SJ, Lee YJ, Lee SJ, Hong BK, Kang WC, Lee JY, et al. Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial. JAMA. 2023;329(13):1078-1087. doi:10.1001/jama.2023.2487 · PMID 36877807G2
  84. Howard JP, Wood FA, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, et al. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment. J Am Coll Cardiol. 2021;78(12):1210-1222. doi:10.1016/j.jacc.2021.07.022 · PMID 34531021C4
  85. Hundley WG, D'Agostino R Jr, Crotts T, Craver K, Hackney MH, Jordan JH, et al. Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment. NEJM Evid. 2022;1(9). doi:10.1056/evidoa2200097 · PMID 36908314C6
  86. Jiménez-Méndez C, Vázquez-García R, Delgado W, Bartolome D, Silva E. Long-term impact of telemedicine for lipid control after an acute coronary syndrome. Eur J Prev Cardiol. 2025;pii: zwaf630. doi: 10.1093/eurjpc/zwaf630. doi:10.1093/eurjpc/zwaf630 · PMID 41045520C8G3
  87. Jiménez-Méndez C, Vázquez-García R, Delgado W, Bartolome D, Silva E. Long-term impact of an intensive telemedicine-based strategy for lipid management. Rev Esp Cardiol (Engl Ed). 2026;79(3):273-275. doi:10.1016/j.rec.2025.05.013 · PMID 40581226G3
  88. Kalstad AA, Myhre PL, Laake K, Tveit SH, Schmidt EB, Smith P, et al. Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial. Circulation. 2021;143(6):528-539. doi:10.1161/CIRCULATIONAHA.120.052209 · PMID 33191772C5G2
  89. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849-61. doi:10.1016/S0140-6736(05)67667-2 · PMID 16310551C5G2I1
  90. Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, et al. Development and Validation of the American Heart Association's PREVENT Equations. Circulation. 2024;149(6):430-449. doi:10.1161/CIRCULATIONAHA.123.067626 · PMID 37947085C7
  91. Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400(10349):380-390. doi:10.1016/S0140-6736(22)00916-3 · PMID 35863366C5G2I1
  92. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357(22):2248-61. doi:10.1056/NEJMoa0706201 · PMID 17984166C5G2
  93. Klug EQ, Llerena S, Burgess LJ, Fourie N, Scott R, Vest J, et al. Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial. JAMA Cardiol. 2024;9(9):800-807. doi:10.1001/jamacardio.2024.1659 · PMID 38958989G5
  94. Knowlton KU, Navar AM, Anderson JL, Brown AS, Muhlestein JB, Kleeman K, et al. Low-Density Lipoprotein Cholesterol Lowering With Inclisiran Plus Usual Care in Recent Acute Coronary Syndrome: VICTORION-INCEPTION, a Randomized, Controlled, Open-Label Trial. J Am Heart Assoc. 2026;15(10):e043655. doi:10.1161/JAHA.125.043655 · PMID 42132192H4
  95. Koren MJ, Vega RB, Agrawal N, Xu Y, Barbour AM, Yu H, et al. An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT Randomized Trial. J Am Coll Cardiol. 2025;85(21):1996-2007. doi:10.1016/j.jacc.2025.03.499 · PMID 40167413G5
  96. Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, et al. Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). J Am Coll Cardiol. 2019;74(20):2452-2462. doi:10.1016/j.jacc.2019.08.010 · PMID 31479722G2H4I1
  97. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946. doi:10.1093/eurheartj/ehac361 · PMID 36036785C7G1H3
  98. Køber L, Adamo M, Ruwald AC, Tomasoni D, Anderson LJ, Andersson C, et al. 2026 ESC Guidelines for the management of heart failure. Eur Heart J. 2026;47(38):5346-5457. doi:10.1093/eurheartj/ehag100 · PMID 42661420G1
  99. Laffin LJ, Bruemmer D, Garcia M, Brennan DM, McErlean E, Jacoby DS, et al. Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers. J Am Coll Cardiol. 2023;81(1):1-12. doi:10.1016/j.jacc.2022.10.013 · PMID 36351465G2
  100. Laffin LJ, Nicholls SJ, Scott RS, Clifton PM, Baker J, Sarraju A, et al. Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. N Engl J Med. 2025;393(21):2119-2130. doi:10.1056/NEJMoa2511778 · PMID 41211945G5
  101. Laffin LJ, Nicholls SJ, Scott RS, Clifton PM, Koops R, Sarraju A, et al. Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310. N Engl J Med. 2026;395(13):1343-1345. doi:10.1056/NEJMc2609825 · PMID 42663980G5
  102. Lamiquiz-Moneo I, Civeira F, Mateo-Gallego R, Laclaustra M, Moreno-Franco B, Tejedor MT, et al. Diagnostic yield of sequencing familial hypercholesterolemia genes in individuals with primary hypercholesterolemia. Rev Esp Cardiol (Engl Ed). 2021;74(8):664-673. doi:10.1016/j.rec.2020.06.003 · PMID 32660911G3H2
  103. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-35. doi:10.1056/NEJMoa050461 · PMID 15755765C5G2I1
  104. Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc. 2019;8(7):e011662. doi:10.1161/JAHA.118.011662 · PMID 30922146G2
  105. Lee YJ, Hong SJ, Kang WC, Hong BK, Lee JY, Lee JB, et al. Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial. BMJ. 2023;383:e075837. doi:10.1136/bmj-2023-075837 · PMID 37852649C5
  106. Leosdottir M, Schubert J, Brandts J, Gustafsson S, Cars T, Sundström J, et al. Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry. J Am Coll Cardiol. 2025;85(15):1550-1564. doi:10.1016/j.jacc.2025.02.007 · PMID 40240093C8
  107. Leucker TM, Blaha MJ, Jones SR, Vavuranakis MA, Williams MS, Lai H, et al. Effect of Evolocumab on Atherogenic Lipoproteins During the Peri- and Early Postinfarction Period: A Placebo-Controlled, Randomized Trial. Circulation. 2020;142(4):419-421. doi:10.1161/CIRCULATIONAHA.120.046320 · PMID 32718248H4
  108. León-Jiménez D, Martínez-Hervás S, Lois-Martínez N, Jericó-Alba C, Martínez-Soriano MJ, Royuela-Juncadella M, et al. Effectiveness, safety, and treatment persistence of bempedoic acid in a Spanish real-world cohort. J Clin Lipidol. 2026;20(9):1933-1945. doi:10.1016/j.jacl.2026.07.033 · PMID 42580964G3
  109. Lok CE, Farkouh M, Hemmelgarn BR, Moist LM, Polkinghorne KR, Tomlinson G, et al. Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis. N Engl J Med. 2026;394(2):128-137. doi:10.1056/NEJMoa2513032 · PMID 41201837C6G2
  110. Luirink IK, Wiegman A, Kusters DM, Hof MH, Groothoff JW, de Groot E, et al. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia. N Engl J Med. 2019;381(16):1547-1556. doi:10.1056/NEJMoa1816454 · PMID 31618540C6
  111. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244 · PMID 36017568C6G1
  112. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455 · PMID 31504418C3C4C6C7C8D1G1G5H1H3H4I1I2
  113. Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359-4378. doi:10.1093/eurheartj/ehaf190 · PMID 40878289C3C4C6C7C8D1G1G2G5H1H3H4I1I2
  114. Machline-Carrion MJ, Santo K, Girotto AN, Raupp P, Pereira PM, Monfardini F, et al. Digitally Enabled Quality Improvement Intervention and LDL-C Control in Atherosclerotic Cardiovascular Disease: The SAPPHIRE-LDL Cluster Randomized Clinical Trial. JAMA Cardiol. 2026;11(9):810-819. doi:10.1001/jamacardio.2026.2510 · PMID 42485013G2
  115. Mafham MM, Zayed MG, Collins R, Sabatine MS, Armitage J, Brittain D, et al. HPS-4/TIMI 65/ORION-4: A double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease: Trial design, recruitment, and baseline characteristics. Am Heart J. 2026;303:107546. doi:10.1016/j.ahj.2026.107546 · PMID 42567431G5
  116. Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med. 2019;380(1):23-32. doi:10.1056/NEJMoa1811403 · PMID 30415637C5G2I1
  117. Marco-Benedí V, Bea AM, Sánchez Hernández RM, Plana N, Valdivielso P, Civeira F. Dyslipidemia treatment strategies in primary and secondary prevention. Dyslipemia Registry of the Spanish Arteriosclerosis Society. Clin Investig Arterioscler. 2022;34(6):303-310. doi:10.1016/j.arteri.2022.03.007 · PMID 35654677G3
  118. Marco-Benedí V, Cenarro A, Laclaustra M, Larrea-Sebal A, Jarauta E, Lamiquiz-Moneo I, et al. Lipoprotein(a) in hereditary hypercholesterolemia: Influence of the genetic cause, defective gene and type of mutation. Atherosclerosis. 2022;349:211-218. doi:10.1016/j.atherosclerosis.2021.08.009 · PMID 34456049G3
  119. Marco-Benedí V, Bea AM, Ortega E, Zamora A, Gimeno JA, Guijarro C, et al. The Spanish Atherosclerosis Society Dyslipidaemia Registry: Evolution, real-world evidence, and its role in precision medicine. Current status in 2026. Clin Investig Arterioscler. 2026;doi: 10.1016/j.arteri.2026.500958. doi:10.1016/j.arteri.2026.500958 · PMID 42469108G3
  120. Marston NA, Bergmark BA, Alexander VJ, Prohaska TA, Kang YM, Moura FA, et al. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. N Engl J Med. 2026;394(5):429-441. doi:10.1056/NEJMoa2512761 · PMID 41211918G2G5I1
  121. Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013;310(19):2061-8. doi:10.1001/jama.2013.280532 · PMID 24240933H5
  122. Martínez López I, Gómez Cerezo JF, Gámez JM, Egocheaga Cabello I, Castellanos M, Campuzano Ruiz R, et al. Post-event follow-up costs in patients with atherosclerotic cardiovascular disease in Spain. Front Cardiovasc Med. 2024;11:1324537. doi:10.3389/fcvm.2024.1324537 · PMID 38481954H2
  123. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. doi:10.1093/eurheartj/ehad192 · PMID 37622663C6C7G1
  124. Masana L, Díaz Moya G, Pérez de Isla L, HEARTBEAT study investigators. Patients who suffer a first atherosclerotic cardiovascular event while taking statins are often far off of lipid targets. Nutr Metab Cardiovasc Dis. 2024;34(1):90-97. doi:10.1016/j.numecd.2023.09.022 · PMID 38092606G3
  125. Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45(36):3538-3700. doi:10.1093/eurheartj/ehae179 · PMID 39210722C6G1
  126. Milà L, Barrabés JA, Lidón RM, Sambola A, Bañeras J, Oristrell G, et al. Prior adherence to recommended lipid control targets in patients admitted for acute coronary syndrome. Rev Esp Cardiol (Engl Ed). 2020;73(5):376-382. doi:10.1016/j.rec.2019.06.014 · PMID 31706709G3
  127. Miyauchi K, Iwata H, Nishizaki Y, Inoue T, Hirayama A, Kimura K, et al. Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA). Circulation. 2024;150(6):425-434. doi:10.1161/CIRCULATIONAHA.123.065520 · PMID 38873793C5G2
  128. Montalescot G, Ferrari E, Souteyrand G, Bouleti C, Range G, Batias-Moreau L, et al. LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: The AMUNDSEN Randomized Clinical Trial. JAMA. 2026;doi: 10.1001/jama.2026.17302. doi:10.1001/jama.2026.17302 · PMID 42666092G2H4I1
  129. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758-769. doi:10.1016/j.jacl.2015.08.006 · PMID 26687696C4C5G2I1
  130. Mostaza JM, García-Ortiz L, Suárez Tembra MA, Talavera Calle P, Chimeno García J, Escolar Pérez V, et al. Failure of LDL-C goals achievement and underuse of lipid-lowering therapies in patients at high and very high cardiovascular risk: Spanish subset from the European SANTORINI study. Rev Clin Esp (Barc). 2025;225(2):78-84. doi:10.1016/j.rceng.2024.11.004 · PMID 39613100G3
  131. Mostaza JM, Lahoz C, de Yébenes Castro MG, Rubio Campal JM, Velásquez E, Ibarra Gutiérrez A, et al. Usage of lipid-lowering therapies in patients at high and very high cardiovascular risk from Spain: one-year follow-up of the Spanish subpopulation from the European SANTORINI study. Rev Clin Esp (Barc). 2025;225(8):502344. doi:10.1016/j.rceng.2025.502344 · PMID 40675328G3
  132. Nabati M, Janbabai G, Esmailian J, Yazdani J. Effect of Rosuvastatin in Preventing Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer: A Randomized, Single-Blind, Placebo-Controlled Trial. J Cardiovasc Pharmacol Ther. 2019;24(3):233-241. doi:10.1177/1074248418821721 · PMID 30599756C6
  133. Navar AM, Mikhailova E, Catapano AL, Banka P, Blom DJ, Cadena A, et al. A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. N Engl J Med. 2026;394(6):529-539. doi:10.1056/NEJMoa2511002 · PMID 41879224G5
  134. Neilan TG, Quinaglia T, Onoue T, Mahmood SS, Drobni ZD, Gilman HK, et al. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial. JAMA. 2023;330(6):528-536. doi:10.1001/jama.2023.11887 · PMID 37552303C6I1
  135. Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020;324(22):2268-2280. doi:10.1001/jama.2020.22258 · PMID 33190147C5G2I1
  136. Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, et al. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC Cardiovasc Imaging. 2022;15(7):1308-1321. doi:10.1016/j.jcmg.2022.03.002 · PMID 35431172H4
  137. Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, Ballantyne CM, Ray KK, et al. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025;393(1):51-61. doi:10.1056/NEJMoa2415820 · PMID 40337982G5
  138. Nicholls SJ, Nelson AJ, Ray KK, Ballantyne CM, Ditmarsch M, Kling D, et al. Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025;86(14):1046-1056. doi:10.1016/j.jacc.2025.07.056 · PMID 40888776G5
  139. Nicholls SJ, Ni W, Rhodes GM, Nissen SE, Navar AM, Michael LF, et al. Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial. JAMA. 2025;333(3):222-231. doi:10.1001/jama.2024.24017 · PMID 39556768G5
  140. Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, Ballantyne CM, Ray KK, et al. Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial. Nat Med. 2026;32(3):1052-1060. doi:10.1038/s41591-025-04179-4 · PMID 41760952G5
  141. Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, et al. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016;315(15):1580-90. doi:10.1001/jama.2016.3608 · PMID 27039291C4C5G2
  142. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023;388(15):1353-1364. doi:10.1056/NEJMoa2215024 · PMID 36876740C4C5G2I1
  143. Nissen SE, Wang Q, Nicholls SJ, Navar AM, Ray KK, Schwartz GG, et al. Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial. JAMA. 2024;332(23):1992-2002. doi:10.1001/jama.2024.21957 · PMID 39556769G5
  144. Nissen SE, Ni W, Shen X, Wang Q, Navar AM, Nicholls SJ, et al. Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a). N Engl J Med. 2025;392(17):1673-1683. doi:10.1056/NEJMoa2415818 · PMID 40162643G5
  145. O'Donoghue ML, Rosenson RS, Gencer B, López JAG, Lepor NE, Baum SJ, et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med. 2022;387(20):1855-1864. doi:10.1056/NEJMoa2211023 · PMID 36342163G5
  146. Ortega E, Vlacho B, Treserres RP, Mata-Cases M, Altes A, Mauricio D, et al. Severe hypertriglyceridemia prevalence at a primary care setting in Catalonia, Spain. J Clin Lipidol. 2023;17(6):777-787. doi:10.1016/j.jacl.2023.09.002 · PMID 37741728G3H2
  147. Ouchi Y, Sasaki J, Arai H, Yokote K, Harada K, Katayama Y, et al. Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Randomized, Controlled Trial. Circulation. 2019;140(12):992-1003. doi:10.1161/CIRCULATIONAHA.118.039415 · PMID 31434507C5C6G2I1
  148. Oyama K, Takahashi J, Funaki T, Oyamada S, Horiguchi S, Nakamura A, et al. Protocol-Based Implementation of Early Intensive Lipid Management After Acute Coronary Syndrome: The BRIDGE Trial. J Am Coll Cardiol. 2026;pii: S0735-1097(26)07509-1. doi: 10.1016/j.jacc.2026.08.026. doi:10.1016/j.jacc.2026.08.026 · PMID 42671370G2H4
  149. Parhofer KG, Julius U, Herzog AL, Krüger T, Weinmann-Menke J, Heine GH, et al. Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial. Eur Heart J. 2026;47(25):3284-3294. doi:10.1093/eurheartj/ehag073 · PMID 41721795G5
  150. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294(19):2437-45. doi:10.1001/jama.294.19.2437 · PMID 16287954C5G2
  151. Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñiz O, et al. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. J Am Coll Cardiol. 2016;67(11):1278-85. doi:10.1016/j.jacc.2016.01.008 · PMID 26988947G3
  152. Piro V, Fuente E, Romano F, Galván M, Fernández M, Groba MDV, et al. Inclisiran for LDL-C reduction in secondary prevention: Real-world evidence from a homogeneous Spanish cohort with subgroup insights. Clin Investig Arterioscler. 2026;doi: 10.1016/j.arteri.2026.500949. doi:10.1016/j.arteri.2026.500949 · PMID 42248700G3
  153. Párraga-Martínez I, Escobar-Rabadán F, Rabanales-Sotos J, Lago-Deibe F, Téllez-Lapeira JM, Villena-Ferrer A, et al. Efficacy of a Combined Strategy to Improve Low-density Lipoprotein Cholesterol Control Among Patients With Hypercholesterolemia: A Randomized Clinical Trial. Rev Esp Cardiol (Engl Ed). 2018;71(1):33-41. doi:10.1016/j.rec.2017.05.029 · PMID 28652127C8
  154. Pérez de Isla L, Arroyo-Olivares R, Alonso R, Muñiz-Grijalvo O, Díaz-Díaz JL, Zambón D, et al. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry. Rev Esp Cardiol (Engl Ed). 2020;73(10):828-834. doi:10.1016/j.rec.2019.10.028 · PMID 32201274G3
  155. Raal F, Fourie N, Scott R, Blom D, De Vries Basson M, Kayikcioglu M, et al. Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial. Eur Heart J. 2023;44(40):4272-4280. doi:10.1093/eurheartj/ehad596 · PMID 37639462G5
  156. Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):341-50. doi:10.1016/S0140-6736(14)61374-X · PMID 25282520G2
  157. Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020;382(16):1520-1530. doi:10.1056/NEJMoa1913805 · PMID 32197277G2I1
  158. Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020;383(8):711-720. doi:10.1056/NEJMoa2004215 · PMID 32813947G2G5H3I1
  159. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-9. PMID 7968073C5G2I1
  160. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019;380(11):1022-1032. doi:10.1056/NEJMoa1803917 · PMID 30865796G2
  161. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387 · PMID 32187462C5G2I1
  162. Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, et al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279-1289. doi:10.1093/eurjpc/zwaa047 · PMID 33580789G3
  163. Ray KK, Haq I, Bilitou A, Manu MC, Burden A, Aguiar C, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624. doi:10.1016/j.lanepe.2023.100624 · PMID 37090089G3
  164. Ray KK, Aguiar C, Arca M, Connolly DL, Eriksson M, Ferrières J, et al. Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study. Eur J Prev Cardiol. 2024;31(15):1792-1803. doi:10.1093/eurjpc/zwae199 · PMID 38861400G3
  165. Ray KK, Oru E, Rosenson RS, Jones J, Ma X, Walgren J, et al. Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2025;405(10489):1594-1607. doi:10.1016/S0140-6736(25)00507-0 · PMID 40179932G5
  166. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-207. doi:10.1056/NEJMoa0807646 · PMID 18997196C5G2I1
  167. Rosenson RS, Gaudet D, Hegele RA, Ballantyne CM, Nicholls SJ, Lucas KJ, et al. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. N Engl J Med. 2024;391(10):913-925. doi:10.1056/NEJMoa2404147 · PMID 38809174G5
  168. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343-56. doi:10.1056/NEJMoa0804602 · PMID 18765433G2
  169. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341(6):410-8. doi:10.1056/NEJM199908053410604 · PMID 10438259C5I1
  170. Ruiz-García A, Arranz-Martínez E, López-Uriarte B, Rivera-Teijido M, Palacios-Martínez D, Dávila-Blázquez GM, et al. Prevalence of hypertriglyceridemia in adults and related cardiometabolic factors. SIMETAP-HTG study. Clin Investig Arterioscler. 2020;32(6):242-255. doi:10.1016/j.arteri.2020.04.001 · PMID 32534728H2
  171. Ruiz-García A, Arranz-Martínez E, García-Fernández ME, Cabrera-Vélez R, García-Pliego RA, Morales-Cobos LE, et al. Related cardiometabolic factors and prevalence of low HDL-cholesterol levels and atherogenic dyslipidemia. SIMETAP-AD study. Clin Investig Arterioscler. 2021;33(1):19-29. doi:10.1016/j.arteri.2020.06.006 · PMID 33082056H2
  172. Räber L, Ueki Y, Otsuka T, Losdat S, Häner JD, Lonborg J, et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327(18):1771-1781. doi:10.1001/jama.2022.5218 · PMID 35368058H4I1
  173. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664 · PMID 28304224C5G2I1
  174. Sampson M, Ling C, Sun Q, Harb R, Ashmaig M, Warnick R, et al. A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia. JAMA Cardiol. 2020;5(5):540-548. doi:10.1001/jamacardio.2020.0013 · PMID 32101259H5
  175. Santos RD, Ruzza A, Hovingh GK, Wiegman A, Mach F, Kurtz CE, et al. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020;383(14):1317-1327. doi:10.1056/NEJMoa2019910 · PMID 32865373G2
  176. Sarraju A, Brennan D, Hayden K, Stronczek A, Goldberg AC, Michos ED, et al. Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025;405(10491):1757-1768. doi:10.1016/S0140-6736(25)00721-4 · PMID 40347969G5
  177. Schubert J, Leosdottir M, Lindahl B, Westerbergh J, Melhus H, Modica A, et al. Intensive early and sustained lowering of non-high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry. Eur Heart J. 2024;45(39):4204-4215. doi:10.1093/eurheartj/ehae576 · PMID 39217499G3H4
  178. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097-2107. doi:10.1056/NEJMoa1801174 · PMID 30403574C5G2I1
  179. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287(24):3215-22. doi:10.1001/jama.287.24.3215 · PMID 12076217C5I1
  180. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-58. doi:10.1016/S0140-6736(03)12948-0 · PMID 12686036C5G2I1
  181. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301-7. doi:10.1056/NEJM199511163332001 · PMID 7566020C5G2I1
  182. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-30. doi:10.1016/s0140-6736(02)11600-x · PMID 12457784C5C6G2I1
  183. Steg PG, Goodman SG, Jukema JW, Martens P, Zirlik A, Bhatt DL, et al. Design of VICTORION-2 Prevent: A randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease. Am Heart J. 2026;300:107493. doi:10.1016/j.ahj.2026.107493 · PMID 42203164G5
  184. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012-22. doi:10.1093/eurheartj/ehv043 · PMID 25694464C4G1
  185. Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, Hegele RA, Arca M, Ballantyne CM, et al. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. N Engl J Med. 2024;390(19):1781-1792. doi:10.1056/NEJMoa2400201 · PMID 38587247G2G5H3I1
  186. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376(9753):1658-69. doi:10.1016/S0140-6736(10)60310-8 · PMID 21067805C5G2
  187. Sánchez-Hernández RM, Civeira F, Stef M, Perez-Calahorra S, Almagro F, Plana N, et al. Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship. Circ Cardiovasc Genet. 2016;9(6):504-510. doi:10.1161/CIRCGENETICS.116.001545 · PMID 27784735G3H2
  188. Sánchez-Hernández RM, Ibarretxe D, Fuentes Jiménez F, Martínez-Hervás S, Blanco-Echevarría A, Cortés Rodríguez B, et al. Homozygous Familial Hypercholesterolemia in Spain: Data From Registry of the Spanish Atherosclerosis Society. J Clin Endocrinol Metab. 2025;110(8):2280-2287. doi:10.1210/clinem/dgae784 · PMID 39514762G3
  189. Sánchez-Ramos A, Fernández-Labandera C, Vallejo-Vaz AJ, Bonacho EC, Quevedo-Aguado L, Catalina-Romero C, et al. Prevalence of familial hypercholesterolemia phenotype and ten-year risk of cardiovascular events in a working population in primary prevention: The ICARIA study. Atherosclerosis. 2021;338:39-45. doi:10.1016/j.atherosclerosis.2021.11.007 · PMID 34785430H2
  190. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231-9. doi:10.1016/S0140-6736(08)61240-4 · PMID 18757089C5G2
  191. Thavendiranathan P, Houbois C, Marwick TH, Kei T, Saha S, Runeckles K, et al. Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines. Eur Heart J Cardiovasc Pharmacother. 2023;9(6):515-525. doi:10.1093/ehjcvp/pvad031 · PMID 37120736C6
  192. Tromp TR, Hartgers ML, Hovingh GK, Vallejo-Vaz AJ, Ray KK, Soran H, et al. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet. 2022;399(10326):719-728. doi:10.1016/S0140-6736(21)02001-8 · PMID 35101175G3
  193. Vafai SB, Täubel J, Ashdown T, Patel RS, Diamondali S, Cegla J, et al. In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia. N Engl J Med. 2026;395(7):648-659. doi:10.1056/NEJMoa2601283 · PMID 42187087G5
  194. Vallejo-Vaz AJ, Arroyo-Olivares R, Alonso R, Gidding SS, Muñiz-Grijalvo O, de Andrés R, et al. Cholesterol-lowering therapy from childhood/adolescence and long-term outcomes in familial hypercholesterolaemia: the SAFEHEART study. Eur Heart J. 2026;pii: ehag349. doi: 10.1093/eurheartj/ehag349. doi:10.1093/eurheartj/ehag349 · PMID 42290618G3H3
  195. Vavuranakis MA, Jones SR, Ziogos E, Blaha MJ, Williams MS, Foran P, et al. The Trajectory of Lipoprotein(a) During the Peri- and Early Postinfarction Period and the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition. Am J Cardiol. 2022;171:1-6. doi:10.1016/j.amjcard.2022.01.058 · PMID 35314069H4
  196. Velasco A, Costa R, Alonso-Carrillo J, de Castro M, Hayes Meizoso C, Blanco-Echevarria A, et al. First real-world experience with inclisiran in Spain: Efficacy, safety, and prescription patterns in clinical practice. Clin Investig Arterioscler. 2026;doi: 10.1016/j.arteri.2026.500957. doi:10.1016/j.arteri.2026.500957 · PMID 42463340G3
  197. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi:10.1093/eurheartj/ehab484 · PMID 34458905C6D1G1I2
  198. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415-3537. doi:10.1093/eurheartj/ehae177 · PMID 39210710C3C6G1I1I2
  199. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238-48. doi:10.1056/NEJMoa043545 · PMID 16034009C5C6G2I1
  200. Watts GF, Rosenson RS, Hegele RA, Goldberg IJ, Gallo A, Mertens A, et al. Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk. N Engl J Med. 2025;392(2):127-137. doi:10.1056/NEJMoa2409368 · PMID 39225259G5H3I1
  201. Wiegman A, Bourbon M, Freiberger T, Gidding SS, Greber-Platzer S, Groselj U, et al. Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement. Eur Heart J. 2026;47(26):3324-3346. doi:10.1093/eurheartj/ehag382 · PMID 42179051C6G1H3
  202. Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. N Engl J Med. 2019;381(6):531-542. doi:10.1056/NEJMoa1715944 · PMID 31390500G2G5H3I1
  203. Wood DA, Jennings CS, Kotseva K, Adamska A, Erlund I, Ganly S, et al. ESC Guidelines on prevention and rehabilitation in coronary heart disease and current practice: the EUROASPIRE VI survey. Eur Heart J. 2026;pii: ehag741. doi: 10.1093/eurheartj/ehag741. doi:10.1093/eurheartj/ehag741 · PMID 42666091G3
  204. Wood FA, Howard JP, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, et al. N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects. N Engl J Med. 2020;383(22):2182-2184. doi:10.1056/NEJMc2031173 · PMID 33196154C4
  205. Writing Committee Members, Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276. doi:10.1161/CIR.0000000000001423 · PMID 41824552C3C6C7C8G1H3I1
  206. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090-8. doi:10.1016/S0140-6736(07)60527-3 · PMID 17398308C5G2
  207. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016;374(21):2021-31. doi:10.1056/NEJMoa1600176 · PMID 27040132C5G2I1
  208. Zamora A, Masana L, Comas-Cufí M, Vila À, Plana N, García-Gil M, et al. Familial hypercholesterolemia in a European Mediterranean population-Prevalence and clinical data from 2.5 million primary care patients. J Clin Lipidol. 2017;11(4):1013-1022. doi:10.1016/j.jacl.2017.05.012 · PMID 28826564G3H2
  209. Zamora A, Masana L, Comas-Cufi M, Plana N, Vila À, García-Gil M, et al. Number of Patients Eligible for PCSK9 Inhibitors Based on Real-world Data From 2.5 Million Patients. Rev Esp Cardiol (Engl Ed). 2018;71(12):1010-1017. doi:10.1016/j.rec.2018.03.003 · PMID 29606363G3
  210. Ziogos E, Vavuranakis MA, Harb T, Foran PL, Blaha MJ, Jones SR, et al. Lipoprotein(a) concentrations in acute myocardial infarction patients are not indicative of levels at six month follow-up. Eur Heart J Open. 2023;3(2):oead035. doi:10.1093/ehjopen/oead035 · PMID 37095769H4
  211. Zoungas S, Wolfe R, Moran C, Nicholls SJ, Cloud GC, Reid CM, et al. Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older Adults. N Engl J Med. 2026;395(13):1259-1272. doi:10.1056/NEJMoa2607314 · PMID 42670961C5C6G2I1

Otros documentos con DOI (2)

  1. Ródenas E, Escalona R, Pariggiano I, Oristrell G, Miranda B, Belahnech Y, et al. Individual trends in LDL-C control in patients with previous myocardial infarction. REC: CardioClinics. 2020;55(1):23-29. doi:10.1016/j.rccl.2019.10.001G3
  2. Vivas D, Escobar C, Cordero A, Fernández-Olmo R, Oterino A, Blanco-Echevarría A, et al. Uso de nuevas terapias hipolipemiantes en la práctica clínica. Consenso SEC/SEA/SEEN/SEMFYC/SEMERGEN/SEMG/SEN/SEACV/S.E.N. REC: CardioClinics. 2024;59(4):310-321. doi:10.1016/j.rccl.2024.06.002G1

Fichas técnicas (CIMA, AEMPS) (37)

  1. Ficha técnica de alirocumab. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 1151031008C1C3C4C5C7H1H4I1I2
  2. Ficha técnica de atorvastatina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 61716C1C3C4C5C7E3H1H4I1I2
  3. Ficha técnica de atorvastatina y ezetimiba. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 79224C3C4
  4. Ficha técnica de bezafibrato. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 55728C3C5I1I2
  5. Ficha técnica de bezafibrato. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 57150C3I1
  6. Ficha técnica de colesevelam. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 03268004C3I1I2
  7. Ficha técnica de colestiramina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 49340C3I1I2
  8. Ficha técnica de colestiramina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 56701C3I1
  9. Ficha técnica de evinacumab. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 1211551001C3G5H3I1I2
  10. Ficha técnica de evolocumab. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 1151016002C1C3C4C5C7G5H1H4I1I2
  11. Ficha técnica de ezetimiba. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 65376C1C3C4C5C7H1I1I2
  12. Ficha técnica de fenofibrato. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 56864C3H1I1
  13. Ficha técnica de fenofibrato. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 60176C3
  14. Ficha técnica de fenofibrato. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 63533C3
  15. Ficha técnica de fenofibrato. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 66861C1C3C5I1I2
  16. Ficha técnica de fluvastatina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 64648C3C4C5I1I2
  17. Ficha técnica de fluvastatina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 69886C3
  18. Ficha técnica de gemfibrozilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 58832C1C3C5I1I2
  19. Ficha técnica de gemfibrozilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 61026C3I1
  20. Ficha técnica de icosapento de etilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 1201524001C1C3C5C7E3H1I1I2
  21. Ficha técnica de inclisirán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 1201494001C1C3C4C5C7G5H1H4I1I2
  22. Ficha técnica de lomitapida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 113851002C3G5H3I1I2
  23. Ficha técnica de lovastatina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 58757C3C4C5I1I2
  24. Ficha técnica de olezarsén. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 1251969001C3G5H3I1I2
  25. Ficha técnica de pitavastatina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 73041C3C4C5I1I2
  26. Ficha técnica de pitavastatina y ezetimiba. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 91035C3C4
  27. Ficha técnica de plozasirán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 1262041001C3G5H3I1I2
  28. Ficha técnica de pravastatina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 59029C3C4C5I1I2
  29. Ficha técnica de registro 09591003. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 09591003C3I2
  30. Ficha técnica de rosuvastatina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 70243C1C3C4C5H4I1I2
  31. Ficha técnica de rosuvastatina y ezetimiba. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 79053C3C4
  32. Ficha técnica de simvastatina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 58845C1C3C4C5H4I1I2
  33. Ficha técnica de simvastatina y ezetimiba. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 66513C3C4
  34. Ficha técnica de volanesorsén. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 1191360C3G5H3I1I2
  35. Ficha técnica de ácido bempedoico. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 1201425002C1C3C4C5C7H1I1I2
  36. Ficha técnica de ácido bempedoico y ezetimiba. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 1201424002C3C4I1
  37. Ficha técnica de ácidos omega-3 ésteres etílicos. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 25/10/2026. CIMA, registro 65476C1C3C5E3I1I2
La lista se hace sola con lo que citan las páginas de este ESPACIO (PubMed por el PMID; el DOI, en PubMed o en Crossref; las fichas técnicas, en CIMA; los estudios en marcha, en ClinicalTrials.gov) y se rehace cada vez que se actualiza el ESPACIO; seis autores y «et al.», como pide el estilo Vancouver.

Actualidad

Formación

CardioTeca

Legal

La información que figura en CardioTeca.com está dirigida exclusivamente al profesional sanitario facultado para prescribir o dispensar medicamentos, por lo que se requiere una formación especializada para su correcta interpretación. El acceso a algunas secciones se realiza mediante contraseña, y sólo está disponible para profesionales sanitarios. Aunque el sitio web CardioTeca.com está dirigido a profesionales de la salud, la información médica visible en su área pública es de libre acceso. Por ello, queremos aclarar que el uso de estos contenidos por parte de la población no reemplaza en ningún momento la relación entre el médico y el paciente. Para obtener información específica sobre un caso concreto consulte siempre a su médico. En CardioTeca.com empleamos inteligencia artificial como herramienta de apoyo editorial, bajo supervisión de nuestro equipo médico.